Bellerophon Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2015 to Q3 2023

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Bellerophon Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2015 to Q3 2023.
Bellerophon Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2023 was 78.5 %, a 110% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2023	78.5	+41.2	+110%	Sep 30, 2023
Q2 2023	82.4	+53.6	+187%	Jun 30, 2023
Q1 2023	65.1	+40.2	+161%	Mar 31, 2023
Q4 2022	56.3	+32	+132%	Dec 31, 2022
Q3 2022	37.3	+11	+41.6%	Sep 30, 2022
Q2 2022	28.7	+2.14	+8.04%	Jun 30, 2022
Q1 2022	24.9	+0.61	+2.51%	Mar 31, 2022
Q4 2021	24.3	-5.71	-19.1%	Dec 31, 2021
Q3 2021	26.4	-11.1	-29.7%	Sep 30, 2021
Q2 2021	26.6	-29.7	-52.8%	Jun 30, 2021
Q1 2021	24.3	-128	-84%	Mar 31, 2021
Q4 2020	30	-99.6	-76.9%	Dec 31, 2020
Q3 2020	37.5	-106	-73.9%	Sep 30, 2020
Q2 2020	56.3	-139	-71.2%	Jun 30, 2020
Q1 2020	152	-685	-81.8%	Mar 31, 2020
Q4 2019	130	-4.61K	-97.3%	Dec 31, 2019
Q3 2019	144	+3.23K		Sep 30, 2019
Q2 2019	196	-1.61K	-89.2%	Jun 30, 2019
Q1 2019	837	+0.01	+0%	Mar 31, 2019
Q4 2018	4.74K	+3.88K	+451%	Dec 31, 2018
Q3 2018	-3.09K	-3.34K	-1323%	Sep 30, 2018
Q2 2018	1.81K	+1.63K	+907%	Jun 30, 2018
Q1 2018	837	+753	+898%	Mar 31, 2018
Q4 2017	861	+823	+2191%	Dec 31, 2017
Q3 2017	252	+224	+783%	Sep 30, 2017
Q2 2017	179	+153	+581%	Jun 30, 2017
Q1 2017	83.9	+59.7	+248%	Mar 31, 2017
Q4 2016	37.6	+15.5	+70.4%	Dec 31, 2016
Q3 2016	28.6	+4.29	+17.6%	Sep 30, 2016
Q2 2016	26.4			Jun 30, 2016
Q1 2016	24.1			Mar 31, 2016
Q4 2015	22			Dec 31, 2015
Q3 2015	24.3			Sep 30, 2015

* An asterisk sign (*) next to the value indicates that the value is likely invalid.